Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Fisher

Showing results (1-10 of 498) with videos related to

Pageof 50
Sort By:
Cutis|August 1, 1977
Recurrent multiple pyogenic granuloma with multiple satellites. Features of Masson's hemangiomaI Fisher
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 2, 2017
Salm-Net: a network for human salmonella surveillance in EuropeI Fisher
The Cancer Journal From Scientific American|April 9, 1998
Relapse after successful treatment with immunotherapy: lessons for the futureR I Fisher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Advanced insights into the biology of malignant lymphomasRichard I Fisher
Cancer|November 1, 1994
Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 yearsR I Fisher
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Report of workshop 5: early high-dose chemotherapyR I Fisher
Important Advances in Oncology|January 1, 1990
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphomaR I Fisher
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?Richard I Fisher
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHLRichard I Fisher
Cancer Treatment Reports|April 1, 1982
Implications of persistent T cell abnormalities for the etiology of Hodgkin's diseaseR I Fisher
Pageof 50

Showing results (1-10 of 498) with videos related to

Sort By:
Pageof 50
Cutis|August 1, 1977
Recurrent multiple pyogenic granuloma with multiple satellites. Features of Masson's hemangiomaI Fisher
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 2, 2017
Salm-Net: a network for human salmonella surveillance in EuropeI Fisher
The Cancer Journal From Scientific American|April 9, 1998
Relapse after successful treatment with immunotherapy: lessons for the futureR I Fisher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Advanced insights into the biology of malignant lymphomasRichard I Fisher
Cancer|November 1, 1994
Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 yearsR I Fisher
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Report of workshop 5: early high-dose chemotherapyR I Fisher
Important Advances in Oncology|January 1, 1990
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphomaR I Fisher
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?Richard I Fisher
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHLRichard I Fisher
Cancer Treatment Reports|April 1, 1982
Implications of persistent T cell abnormalities for the etiology of Hodgkin's diseaseR I Fisher
Pageof 50